Biotech stocks slumped Wednesday as top 2% names took the hardest hit
CLMBCULLRAPT
Statements (2)
- Bearish
Biotech stocks slumped Wednesday as top 2% names took the hardest hit.
- Bearish
Rapport Therapeutics, Climb Bio, and Cullinan Therapeutics are likely to see significant price declines due to their inclusion in the top 2% of biotech stocks facing the hardest hit.